TY - JOUR
T1 - Fear of hypoglycemia and sleep in children with type 1 diabetes and their parents
AU - Schierloh, Ulrike
AU - Aguayo, Gloria A.
AU - Fichelle, Muriel
AU - De Melo Dias, Cindy
AU - Schritz, Anna
AU - Vaillant, Michel
AU - Barnard-Kelly, Katharine
AU - Cohen, Ohad
AU - Gies, Inge
AU - de Beaufort, Carine
N1 - Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This is an investigator-initiated study. Medtronic contributed in kind to the devices (insulin pumps, transmitter, I-Pro 2) and to the accessories (glucose sensors).
Publisher Copyright:
Copyright © 2024 Schierloh, Aguayo, Fichelle, De Melo Dias, Schritz, Vaillant, Barnard-Kelly, Cohen, Gies and de Beaufort.
PY - 2024/12/16
Y1 - 2024/12/16
N2 - Aims: To compare impact of pump treatment and continuous glucose monitoring (CGM) with predictive low glucose suspend (SmartGuard) or user initiated CGM (iscCGM) on sleep and hypoglycemia fear in children with type 1 Diabetes and parents. Methods: Secondary analysis of data from 5 weeks pump treatment with iscCGM (A) or SmartGuard (B) open label, single center, randomized cross-over study was performed. At baseline and end of treatment arms, sleep and fear of hypoglycemia were evaluated using ActiGraph and questionnaires. Results: 31 children (6-14 years, male: 50%) and 30 parents (28-55 years) participated. Total sleep minutes did not differ significantly for children (B vs. A: -9.27; 95% CI [-24.88; 6.34]; p 0.26) or parents (B vs. A: 5.49; 95% CI [-8.79; 19.77]; p 0.46). Neither daytime sleepiness nor hypoglycemia fear in children or parents differed significantly between the systems. Neither group met recommended sleep criteria. Conclusion: Lack of sleep and fear of hypoglycemia remain a major burden for children with diabetes and their parents. Whilst no significant differences between the systems were found, future technology should consider psychosocial impacts of diabetes and related technologies on children and parents’ lived experience to ensure parity of esteem between physical and mental health outcomes. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03103867.
AB - Aims: To compare impact of pump treatment and continuous glucose monitoring (CGM) with predictive low glucose suspend (SmartGuard) or user initiated CGM (iscCGM) on sleep and hypoglycemia fear in children with type 1 Diabetes and parents. Methods: Secondary analysis of data from 5 weeks pump treatment with iscCGM (A) or SmartGuard (B) open label, single center, randomized cross-over study was performed. At baseline and end of treatment arms, sleep and fear of hypoglycemia were evaluated using ActiGraph and questionnaires. Results: 31 children (6-14 years, male: 50%) and 30 parents (28-55 years) participated. Total sleep minutes did not differ significantly for children (B vs. A: -9.27; 95% CI [-24.88; 6.34]; p 0.26) or parents (B vs. A: 5.49; 95% CI [-8.79; 19.77]; p 0.46). Neither daytime sleepiness nor hypoglycemia fear in children or parents differed significantly between the systems. Neither group met recommended sleep criteria. Conclusion: Lack of sleep and fear of hypoglycemia remain a major burden for children with diabetes and their parents. Whilst no significant differences between the systems were found, future technology should consider psychosocial impacts of diabetes and related technologies on children and parents’ lived experience to ensure parity of esteem between physical and mental health outcomes. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03103867.
KW - children
KW - fear of hypoglycemia
KW - iscCGM
KW - parents
KW - sensor augmented pump
KW - sleep
KW - type 1 diabetes (T1D)
UR - https://www.scopus.com/pages/publications/85213549841
U2 - 10.3389/fendo.2024.1419502
DO - 10.3389/fendo.2024.1419502
M3 - Article
AN - SCOPUS:85213549841
SN - 1664-2392
VL - 15
JO - Frontiers in Endocrinology
JF - Frontiers in Endocrinology
M1 - 1419502
ER -